Healthcare and Pharmaceuticals industry

Global Multiple Sclerosis Therapeutics Market Size Share Forecast 2024




 

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The multiple sclerosis therapeutic agents are intended to promote neurorepair and neuroprotection to prevent disease progression. The disease modifying therapeutics are currently under clinical development to specifically target the disease while avoiding frequent therapeutic administrations. A variety of corticosteroids, immunosuppressants and monoclonal antibodies are approved and recommended to reduce inflammation in multiple sclerosis. The complex nature of disease with its unique individual patient course renders variable clinical outcomes in different patients. Although there is no cure for multiple sclerosis, the currently available therapeutics modify the disease course, accelerate recovery from attacks, and help in managing symptoms.
Market Dynamics
The major factors driving growth of the multiple sclerosis therapeutics market include rise in research and development ultimately leading to the launch of novel drug candidates and the rising prevalence of the condition in children. For instance, in 2014, Plegridy (peginterferon beta-1a) manufactured by Biogen, a disease modifying therapy was approved for the long-term treatment of relapsing forms of multiple sclerosis. According to Multiple Sclerosis Society, approximately five to ten per cent of people with MS experienced their first symptoms before the age of 16. However, the inability of drugs to prevent disease progression and disability, side effects of the approved drugs such as increased risk of infections, flu-like symptoms and progressive multifocal leukoencephalopathy (PML), a viral disease of the brain are the factors hindering market growth.
Key features of the study:

This report provides in-depth analysis of multiple sclerosis therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global multiple sclerosis therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Novartis AG, Teva Pharmaceuticals Industries Ltd., Sanofi Genzyme, Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, market expansion, and marketing tactics
The global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the multiple sclerosis therapeutics market

Detailed Segmentation:

Global Multiple Sclerosis Therapeutics Market, By Drug Class:

Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others

Global Multiple Sclerosis Therapeutics Market, By Route of Administration:

Oral
Injection

Global Multiple Sclerosis Therapeutics Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

Global Multiple Sclerosis Therapeutics Market, By Geography:

North America

By Drug Class:

Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others

By Route of Administration:

Oral
Injection

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

U.S.
Canada


Latin America

By Drug Class:

Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others

By Route of Administration:

Oral
Injection

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

Brazil
Mexico
Argentina
Rest of Latin America


Europe

By Drug Class:

Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others

By Route of Administration:

Oral
Injection

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe


Asia Pacific

By Drug Class:

Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others

By Route of Administration:

Oral
Injection

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific


Middle East

By Drug Class:

Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others

By Route of Administration:

Oral
Injection

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

GCC
Israel
Rest of Middle East


Africa

By Drug Class:

Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others

By Route of Administration:

Oral
Injection

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

By Country:

South Africa
Central Africa
North Africa



Company Profiles

Novartis AG*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Teva Pharmaceuticals Industries Ltd.
Sanofi S.A.
Bayer AG
Pfizer, Inc.
Biogen Idec
Merck & Co., Inc.
AbbVie, Inc.


 “*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
? Market Definition and Scope
o Executive Summary
? Market Snippet, By Drug Class
? Market Snippet, By Route of Administration
? Market Snippet, By Distribution Channel
? Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
? Drivers
? Restraints
? Market Opportunities
? Market Trends
o Regulatory Scenario
o Reimbursement Scenario
o Alternative Therapies
o Pipeline Analysis
o Supply Chain Analysis
o PEST Analysis
o Epidemiology
4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Beta Interferon
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Corticosteroids
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Monoclonal Antibodies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Antineoplastic Agents
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Others
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Oral
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Injection
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Hospital Pharmacies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Retail Pharmacies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o E-Commerce
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
7. Global Multiple Sclerosis Therapeutics Market, By Region, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, By Region, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, For Regions, 2017 - 2025
o North America
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? U.S.
? Canada
o Latin America
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? Brazil
? Mexico
? Rest of Latin America
o Europe
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? Germany
? U.K.
? France
? Italy
? Spain
? Russia
? Rest of Europe
o Asia Pacific
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? China
? India
? Japan
? Australia
? South Korea
? ASEAN
? Rest of APAC
o Middle East
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? GCC
? Israel
? Rest of Middle East
o Africa
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? South Africa
? Central Africa
? North Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3x3 Matrix)
o Company Profiles
? Novartis AG*
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Teva Pharmaceuticals Industries Ltd.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Sanofi S.A.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Bayer AG
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Pfizer, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Biogen Idec
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Merck & Co., Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? AbbVie, Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
o Analyst Views
9. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 35 market data tables and 40 figures on "Multiple Sclerosis Therapeutics Market - Global forecast to 2025".

 



Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.